Author | Lightnews

Chiara Corti, MD @ccortimd.bsky.social · Oct 7

Different reliance on ER signalling for replication and disease heterogeneity

Chiara Corti, MD @ccortimd.bsky.social · May 29

🔬 I’ll be at #ASCO25 to discuss the differential genomic landscape of ER-low vs ER+ and ER- m+ #breastcancer. Join the conversation at Poster Board 50 on 6/2/25, 9:00 AM–12:00 PM! #bcsm @danafarber.bsky.social @danafarbernews.bsky.social @ascocancer.bsky.social

www.asco.org/abstracts-pr...

Differential genomic landscape of estrogen receptor (ER)-low versus ER-positive (ER+) and ER-negative (ER-) metastatic breast cancer (MBC). - ASCO

www.asco.org

1 4

Chiara Corti, MD @ccortimd.bsky.social · May 21

Try and play with it. All the feedback will be welcomed by
@ascocancer.bsky.social and @newsfromgoogle.bsky.social
!

ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.

American Society of Clinical Oncology @ascocancer.bsky.social · May 21

🚨New from ASCO: The ASCO Guidelines Assistant, a new generative AI tool developed in collaboration with Google Cloud, more quickly connects ASCO members with timely and trustworthy information. #ASCO25

Learn more: brnw.ch/21wSP18

2

Chiara Corti, MD @ccortimd.bsky.social · May 15

🚨NEW @ascocancer.bsky.social #EduBook chapter:
@hoperugo.bsky.social, @stolaney1.bsky.social &
I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing

The art of sequencing therapy in the management of breast cancer is a multifaceted challenge that demands the careful integration of clinical trial data, real-world evidence, and individualized patien...

shorturl.at

2

Chiara Corti, MD @ccortimd.bsky.social · Apr 25

In medio stat virtus

Emil Lou, MD,PhD,FACP @cancerassassin1.bsky.social · Apr 24

Right in time for #AACR25: two insightful commentaries this week on the topics of critical thinking and critiquing science and #clinicaltrials results. It can be done with respect, and we need that type of objectivity more than ever

jamanetwork.com/journals/jam...

www.ejcancer.com/article/S095...

1

Chiara Corti, MD @ccortimd.bsky.social · Apr 23

Scientific publishers are under siege by distant buyers, flipping journals to #OpenAccess and raising APCs.

@Nature article explains the game:

“Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue”

www.nature.com/articles/d41...

Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue

Study finds dozens of journals that have hiked their fees and started churning out papers after being acquired by small, recently formed companies.

www.nature.com

1 1

Chiara Corti, MD @ccortimd.bsky.social · Apr 22

“Education is one of the few forces powerful enough to break the cycle of #poverty. It gives children born into hardship the tools to rewrite their story—and shape a future of their own making.”

Reposted by Chiara Corti, MD

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Apr 15

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer.
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

6 5

Reposted by Chiara Corti, MD

mitcriticaldata.bsky.social @mitcriticaldata.bsky.social · Apr 12

www.sciencedirect.com/science/arti...
If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.

Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity

Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among women worldwide. Artificial intelligence (AI) s…

www.sciencedirect.com

1 1 1

Chiara Corti, MD @ccortimd.bsky.social · Apr 12

A big thank you to #LeoCeli and @mitcriticaldata.bsky.social for their consistent support in our research on AI #bias and disparities in breast cancer-related subfields. 🙏🧠

1

Chiara Corti, MD @ccortimd.bsky.social · Apr 12

-> Model accuracy is limited in time and space. AI should be local, iterative, reflective and reflexive. The business model should be assisting health systems with creating, maintaining, curating, evaluating their data pipeline, and most importantly, their "learning pipeline".

1

Chiara Corti, MD @ccortimd.bsky.social · Apr 12

3.we also observed #gender imbalance among first and last authors (male predominance), with #affiliations predominantly from high-income regions.

1

Chiara Corti, MD @ccortimd.bsky.social · Apr 12

2.nearly all patient cohorts originated from high- #income countries, with no representation from low-income settings.

1

Chiara Corti, MD @ccortimd.bsky.social · Apr 12

1.despite a ~300% increase in #AI-related publications between these periods, we found that only 0-25% of studies reported #race / #ethnicity data, with the majority of patients identified as Caucasian.

1

Chiara Corti, MD @ccortimd.bsky.social · Apr 12

In our latest study, we identified 264 studies on AI-powered #mammography interpretation for #breastcancer detection out of 5774 in the two-year periods 2017-2018 and 2022-2023:

1

Chiara Corti, MD @ccortimd.bsky.social · Apr 12

"Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity" shorturl.at/Q7xFo .

1 3

Chiara Corti, MD @ccortimd.bsky.social · Apr 6

From #immunotherapy (IO) failures to new strategies & biotech innovations in metastatic TNBC, to IO timing, chemo backbones, & novel approaches in the early stage. All this & more in our latest review on immune checkpoint inhibitors in #TNBC. shorturl.at/izpbe @dfcibreastonc.bsky.social

4 6

Chiara Corti, MD @ccortimd.bsky.social · Mar 26

Great to stop by #USCAP25 this afternoon to support our team’s work using #MachineLearning to characterize the tumor microenvironment in post-surgical #TNBC specimens after neoadjuvant chemo. @dfcibreastonc.bsky.social @uscap.org

2 5

Chiara Corti, MD @ccortimd.bsky.social · Jan 5

AI-generated content floods literature with poor-quality publications, casts doubt on metrics,
@science.org and Retraction Watch investigation finds.

www.science.org/content/arti...

Shoddy commentaries—a quick and dirty route to higher impact numbers—are on the rise

AI-generated content floods literature with poor-quality publications, casts doubt on metrics, Science and Retraction Watch investigation finds

www.science.org

1

Chiara Corti, MD @ccortimd.bsky.social · Dec 24

Merry Christmas to all. Health truly is our most precious gift - It’s not just a cliché. For some, this season means remembering a loved one, facing a tough diagnosis, starting a new treatment, or getting difficult scan results. My heart is with you. ❤️

1

Chiara Corti, MD @ccortimd.bsky.social · Dec 23

🚨 NY Gov. Kathy Hochul signs bill mandating private insurers cover scalp cooling systems starting Jan 1, 2026. 👏 First state to do so—hopefully paving the way for universal access. #CancerCare #HealthEquity #bcsm

shorturl.at/AXNdm

Breakthrough law offers cancer patients in New York relief for 'scalp-cooling therapy'

New York has become the first state in the country to require insurance coverage for what's called "scalp-cooling therapy," which can reduce hair loss for chemo patients.

shorturl.at

5

Reposted by Chiara Corti, MD

Sarah Sammons MD @drsarahsammons.bsky.social · Dec 13

Great work showing half of patients with metastatic relapse after adjuvant abemaciclib have loss of estrogen expression.

Biopsy remains critical.

#sabcs24 @oncbrothers.bsky.social

Chiara Corti, MD @ccortimd.bsky.social · Dec 13

Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social

2 12

Reposted by Chiara Corti, MD

Guilherme Nader Marta @guinadermarta.bsky.social · Dec 13

Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS

Results are alligned w/ other MammaPrint High 2 results

@oncoalert.bsky.social

6 10

Chiara Corti, MD @ccortimd.bsky.social · Dec 13

Join us in Row 10 to see our poster on outcomes in HER2+ & TNBC pts treated with neoadjuvant tx!

Key findings:
✅ pCR linked to better outcomes
✅ 3-yr RFS/OS varied by cT, cN, & subtype at dx
✅ In RD pts, cT, cN, & subtype stayed prognostic, but not in pCR pts (few events)
#SABCS24 #bcsm

1 4

Chiara Corti, MD @ccortimd.bsky.social · Dec 13

Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social

1 2 10